Stifel analyst Paul Matteis raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $466 from $445 and keeps a Hold rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $518 from $478 at H.C. Wainwright
- Vertex Pharmaceuticals reports Q4 adjusted EPS $5.03, consensus $5.15
- Vertex Pharmaceuticals sees FY26 revenue $12.95B-$13.1B, consensus $13B
- Notable companies reporting after market close
- These Are the Stocks Reporting Earnings Today – February 12, 2026